IMMUNOBIOGRAM®

Immunobiogram® is the only answer for finding possibilities and taking preventive measures

  • World’s only drug and dosage sensitivity platform.
  • Helps settle on immunosuppressant regimens from day one.
  • Eliminates the need for trial and learning.

Value Proposition

Immunobiogram® is the only platform in the world to help assess the sensitivity of immunosuppressant drug and its dosage prior to transplant.

Immunobiogram® helps settle on immunosuppressant regimens from day one.

Immunobiogram® eliminates the need for trial and learning.

Achievements

We work on exclusive basis with BioHope of Spain and Eurofin of the US.

Kit Working Procedure

KIT, and a software to produce meaningful results

Cells are stimulated mimicking the pathologic stimuli which causes rejection in renal transplant (RT).

The activated cells are put in a 3D culture (hydrogel) into channeled wells and then exposed to a panel of immunosuppressants.

A drug concentration gradient is created in the channels and over the cells. Drugs are expected to inhibit activation and proliferation of cells. The more drug concentration, the more effect over the cells is expected.

Cell activation/proliferation after drug exposure is captured by a vital probe and read by a fluorimeter, which raw data is uploaded to a portal where our cloud-based software captures the dose/response effect, by calculating and analyzing typical pharmacological dose/response curves.

The bioassay offers precise and reliable dose-response curves.

The software includes algorithms to study the dose-response curves and to position the patient in the reference population (Biohope’s database)

Global Partnerships

Latest Blogs

Our latest published articles

Interested to know more?

To learn more about Duraent’s innovative organ preservation solutions and transplant technologies, contact us. Discover how we empower medical professionals to deliver life-saving results through groundbreaking products like VitaSmart™ and Belzer UW® Cold Storage Solution.

Request a Demo